I. Introduction
HIV is a lentivirus that causes Acquired Immunodeficiency Syndrome (AIDS), a condition in humans in which progressive failure of the immune system allows life-threatening opportunistic infections and cancers to thrive. Infection with HIV occurs by the transfer of blood, semen, vaginal fluidor breast milk. Within these bodily fluids, HIV is present as both free virus particles and virus within infected immune cells.
Many mathematical models have been derived in order to describe the dynamics of HIV infection in the bloodstream where cell-free-viral spread is the predominant route of viral spread. To model the influence of HIV on T-cell growth, some consideration were made by AlanPerelsonet al. [1] which take into account a number of features of the life history of the virus. However when HIV infects a cell the enzyme reverse transcriptase which it carries, makes a DNA copy of its RNA genome. The viral DNA called the provirus is then duplicated with the cell's DNA every time the cell divides. Thus, once a cell is infected it remains infected for life [1, 2, 3, 4, 5] .
The use of drugs to suppress replication of the HIV has transformed the face of AIDS in the developed world. Pronounced reductions in illness and death have been achieved and healthcare utilization has diminished. HIV therapy has also provided many new insights into the pathogenesis and cellular dynamics of HIV infection.In HIV antiretroviral therapy, drugs act by either blocking the integration of viral RNA into the host cells, or by inhibiting the proper cleavage of viral proteins inside an infected cell. Drugs such as AZT, DDC, DDI and D4T all work as reverse transcriptase inhibitor.
Optimal control of drug for HIV systems requires two components. The first is an understanding of the system in the absence of treatment and the second is a description of the effects of treatment u(t). A number of work has been done on drug treatment in different settings.Kirshneret al. [3] studied a mathematical model whereby the chemotherapy reduces viral production rather than viral infectivity which is more applicable to drugs such as protease inhibitors [4, 5] .
Rosenberget al. [7] used a mathematical modeling with control to develop structured treatment interruption strategies for HIV infection. The goal of the article suggested that mathematical models describing biological processes taking place within a patient over time can be used to design adaptive treatment strategies. Although there has been considerable progressing management of HIV infection using highly active antiretroviral therapies, continuous treatment with these agents involves significant cost and burden, toxicities, development of drug resistance, and problems with adherence; these latter complications are of particular concern in substance abusing individuals.
Nejadet al. [2] presented a fast solution for solving HIV-infection dynamics and chemotherapy optimization based on fuzzy. Two ordinary differential equations systems which models interaction between HIV viruses and human body immune system were used. In addition, Kamyad (AVK) discretization method was introduced and used to solve the mathematical models. The results are then extended to the other domain points of the mathematical model by a fuzzy inference estimator.
Olarteet al. [8] worked on a robust control-based HIV-treatment for infected patients. The dynamics of the immune system's response to infection was modeled using system of nonlinear model with separate efficacy coefficients for protease inhibitor (PIs) and reverse transcriptase inhibitors (RTIs). Numerical simulation results showed that the control law could lead to long-term stable conditions, even in extreme cases.
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In this paper, we deal specifically with when and how treatment should be initiated assuming that treatment can only be continued for a finite time interval until drug resistance is developed. We presented an HIV dynamic immunological in which the optimal control term is the coefficient of the viral infectivity term. The benefit of the treatment is to increase the uninfected T CD  4 cell counts and to decrease the infected cells. We define our objective function to maximize the benefit based on T cell count and minimize the weight factor based on the amount of drug.Pontryagin's maximum principle is used to derive conditions on the optimal control. The optimality system is then solved numerically using a fourth orderRunge-kutta scheme. Graphical representation of numerical simulations is presented with the discussion of the result.
II. Model Formulation
To model these event, the population density of uninfected T CD 
Similarly, immunological models describing the interaction of HIV infection with the immune system was studied by Denise [3] and Shelly [9] .
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Hence the proof. From the above theorem we conclude that the model can be considered well posed and bounded.
III. Optimal Control Formulation
The basic idea of control term [5, 9, 10, 11] 
Considering the problem that often arises in the use of drugs such as harmful side effect, as well as the ineffectiveness of treatment after a certain time due to the capability of the virus to mutate and become resistant [2, 5, 6 ] the state equation (3) 
Combining these 3 cases, the optimal control is characterized as
The state and adjoint differential equation together with the optimal control characterization [12, 13, 14, 15] are solved numerically to illustrate and control the result. Since our state and adjoint equations have conditions at final t , an iterative program can be created to numerically simulate solutions.
IV. Numerical Results and Discussion
The optimal control is obtained by solving theoptimality system consisting of the state system and adjoint variable using an iterative method. We start to solve the state equation with a guess controls over the simulated time using Runge-Kutta scheme of order four. Because of the transversality conditions, the adjoint equation are solved by a backward fourth-order Runge-Kutta scheme using current iterations solution of the state equation and the iteration continues until convergence. This process is repeated and iterations stopped if the values of the unknowns at the previous iterations are very close to the ones at the present iterations.
In order to find the optimal solution, we need initial values for uninfected T cells, latently infected T cells, actively infected cells and the virus population. Equation (1) In this section, we investigate numerically the immunological [9] model without optimal control term and also the effect of the optimal control term with varying weight factor 'B' in equation ( In actual sense the chemotherapy for an infected patient must be less than 2 years, we assume that the HIV antiretroviral therapy period is 360 days.To illustrate the effect of optimal control parameter [2] 
and iterate the numerical scheme for 360 days. Figure 2 . The graph shows the immune system dynamics in contact with HIV during the treatment period. Fig. 2(a-d) shows that increase in weight factor B=30 to B=100 which is inversely related to the percentage of drug given. For the higher weight factor the optimal drug given produces a lower T cell concentration and a higher virus concentration compared to a lower weight factor. In table 2 above, it was observed that the objective functional when treatment is initiated 300 days after the onset of the infection is greater than when initiated at 500 days after the onset of the infection. This revealed that early treatment of the infection is optimal.
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V. Conclusion
In this work, antiretroviral therapy was optimally controlled considering a four compartmental HIV model. We use the pontryagin's maximum to determine optimal dynamic control and then solved numerically to get the optimal control value. It was discovered that for higher weight factor, the optimal treatment parameter produces a lower T cell concentration and a higher virus concentration compared to a lower weight factor.
Also, comparing the value of the objective function ) (u J at the optimal control * u , it was observe that the greatest effect of treatment thus occur when treatment is initiated earliest when T cell counts are highest, after the onset of infection.
The result of the numerical simulation indicates that the rate of uninfected T CD  4 increased and virus population decreased due to treatment parameter u(t).
